{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:04:56Z","timestamp":1790229896908,"version":"4.1.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Olaparib and niraparib are the most widely used poly (ADP-ribose) polymerase inhibitors (PARPis) in clinical practice. However, clinical trial data inadequately capture rare and delayed adverse drug reactions (ADRs) in real-world settings, and a systematic comparison of their ADR profiles is lacking, hindering individualized therapy and risk management. This study systematically analyzes published case reports of ADRs associated with these two drugs to summarize their characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study systematically retrieved case reports on olaparib- and niraparib-related ADRs from seven databases (CNKI, Wanfang, VIP, PubMed, Web of Science, ScienceDirect, and Embase) up to June 2026. Following screening, we extracted baseline data, ADR manifestations, interventions, and outcomes. Adverse events were classified by System Organ Class using the Medical Dictionary for Regulatory Activities (MedDRA), and comparative analyses were conducted on ADR spectra, time-to-onset, and prognosis between the two drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 45 case reports involving 55 patients (68 ADR events) were included, of which 33 cases (40 events) were olaparib-related and 22 cases (28 events) niraparib-related. Seven patients were male (all olaparib users) and 48 females (male-to-female ratio 1:6.8). Most patients were aged &amp;gt;50 years (47 cases, 85.45%), with a mean age of 61.02 \u00b1 10.76 years. Ovarian cancer (OC) was the predominant primary disease (40 cases, 72.73%). Both drugs exhibited a predilection for middle-aged and elderly patients, with the first 30 days of treatment representing the peak period for ADR occurrence; with toxicities affecting the haematological, cutaneous, and respiratory systems in both groups. Distinct toxicity profiles were also observed: olaparib-associated ADRs were multisystemic, involving skin and subcutaneous tissue disorders (13 events, 32.50%), respiratory and mediastinal disorders (11 events, 27.50%), haematological and lymphatic disorders (9 events, 22.50%), and hepatobiliary disorders (4 events, 10.00%), with delayed organ toxicities such as drug-induced liver injury and myelodysplastic syndrome. Temporally, olaparib exhibited a bimodal onset pattern: early cutaneous toxicity followed by mid-to-late pulmonary and hepatobiliary injury. Niraparib-associated ADRs were highly concentrated in the haematological system (20 events, 71.43%), with thrombocytopenia as the core feature, accompanied by neuromuscular toxicities including dysgeusia and elevated creatine kinase; temporally, an early unimodal distribution was observed, with new ADRs significantly reduced after day 91. Twenty-four patients in the olaparib group improved after drug discontinuation, dose adjustment, or symptomatic treatment, seven died due to ADRs or disease progression, and 2 had unreported outcomes; in the niraparib group, 21 improved, 1 showed no improvement, and no drug-related deaths occurred. Upon rechallenge, ADRs recurred mostly within 1 week, and dose reduction effectively lowered recurrence risk. Causality assessment using the Naranjo scale identified 8 cases as \u201cdefinite\u201d, 42 as \u201cprobable\u201d, and 5 as \u201cpossible\u201d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Olaparib and niraparib presented markedly different ADR profiles. Drug selection and monitoring should be individualized based on patient characteristics in clinical practice. Olaparib requires sustained vigilance for cutaneous, pulmonary, and hepatobiliary toxicities, with attention to delayed organ injury; niraparib warrants prioritized prevention of early thrombocytopenia. These findings complement real-world safety evidence for PARP inhibitors and provide a reference for individualized drug selection and stratified safety monitoring in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1935594","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:44:08Z","timestamp":1790228648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective analysis of adverse drug reaction case reports for PARP inhibitors: a comparative study of olaparib and niraparib"],"prefix":"10.3389","volume":"17","author":[{"given":"Dong","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University","place":["Hangzhou, China"]},{"name":"Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ningbo NO.2 Hospital","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyan","family":"Zang","sequence":"additional","affiliation":[{"name":"Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e00735","DOI":"10.14309\/crj.0000000000000735","article-title":"Olaparib-induced immune-mediated liver injury","volume":"9","author":"Alshelleh","year":"2022","journal-title":"ACG Case Rep. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ddg.70400","article-title":"Olaparib-associated cutaneous vasculitis in a patient with breast cancer","author":"\u00c1lvarez-Salafranca","year":"2026","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.07.042","article-title":"Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance olaparib: two case reports and review of the literature","volume":"157","author":"Assaf","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.gore.2023.101162","article-title":"A case of niraparib PARP-inhibitor induced Sweet syndrome in gynecologic cancer","volume":"46","author":"Badiner","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.21037\/atm-21-1883","article-title":"Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials","volume":"9","author":"Bao","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102715","DOI":"10.1016\/j.ijgc.2025.102715","article-title":"Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data","volume":"36","author":"Boccia","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.19960\/j.cnki.issn1005-0698.2022.11.011","article-title":"A case of severe thrombocytopenia induced by niraparib tosylate capsules(in Chinese)","volume":"31","author":"Chen","year":"2022","journal-title":"Chin. J. Pharmacoepidemiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdcr.2023.07.011","article-title":"Olaparib-induced pseudoporphyria in a patient with ovarian cancer","volume":"39","author":"Clark","year":"2023","journal-title":"JAAD Case Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"116685","DOI":"10.1016\/j.ejca.2026.116685","article-title":"Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: results from the phase II NEWTON trial (ENGOT-ov49)","volume":"239","author":"Colombo","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.11604\/pamj.2022.43.216.38384","article-title":"A case of hand-foot syndrome with olaparib","volume":"43","author":"Costa","year":"2022","journal-title":"Pan Afr. Med. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1136\/ejhpharm-2021-002819","article-title":"Pancytopenia in a patient treated with fusidic acid and niraparib: a case report","volume":"30","author":"Damerval","year":"2023","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1182\/blood-2002-03-0686","article-title":"Platelet formation is the consequence of caspase activation within megakaryocytes","volume":"100","author":"de Botton","year":"2002","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e70112","DOI":"10.1002\/jha2.70112","article-title":"Intersecting anemias: PARP inhibitor-induced toxicity and autoimmune Hemolysis\u2014A case report","volume":"6","author":"Dereme","year":"2025","journal-title":"eJHaem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/cdd.2014.202","article-title":"PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors","volume":"22","author":"Farr\u00e9s","year":"2015","journal-title":"Cell Death Differ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e390876(2023)","DOI":"10.1200\/EDBK_390876","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1573397115666190119094736","article-title":"Immune checkpoint inhibitors-related rheumatic diseases: what rheumatologist should know?","volume":"15","author":"Fusun","year":"2019","journal-title":"Curr. Rheumatol. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e927008","DOI":"10.12659\/AJCR.927008","article-title":"Avatrombopag optimizes response to Niraparib by managing thrombocytopenia associated with Poly-ADP ribose polymerase (PARP) inhibition in ovarian cancer and breast cancer: a case series","volume":"21","author":"Gabrail","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/j.seminoncol.2024.01.001","article-title":"PARP inhibitors in ovarian cancer","volume":"51","author":"Goldlust","year":"2024","journal-title":"Semi. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e249177","DOI":"10.1136\/bcr-2022-249177","article-title":"Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer","volume":"15","author":"Gou","year":"2022","journal-title":"BMJ Case Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2147\/CMAR.S169558","article-title":"The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.tpj.6500106","article-title":"Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders","volume":"2","author":"Hahn","year":"2002","journal-title":"Pharmacogenomics J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.resinv.2025.05.002","article-title":"Olaparib-induced interstitial lung disease: a case series analysis","volume":"63","author":"Hattori","year":"2025","journal-title":"Respir. Investig."},{"key":"B25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/cco-24-82","article-title":"Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/1346-8138.15749","article-title":"Cutaneous arteritis during olaparib treatment for ovarian cancer","volume":"48","author":"Iinuma","year":"2021","journal-title":"J. Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/curroncol32090523","article-title":"Pulmonary embolism associated with olaparib in BRCA2-Mutated prostate cancer: a case report","volume":"32","author":"Ishii","year":"2025","journal-title":"Curr. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12890-023-02569-3","article-title":"Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese adverse drug event report database and literature","volume":"23","author":"Ishimoto","year":"2023","journal-title":"BMC Pulm. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.19803\/j.1672-8629.20260261","article-title":"One case of extremely severe thrombocytopenia caused by niraparib tosilate capsules","volume":"23","author":"Jin","year":"2026","journal-title":"Chin. J. Pharmacovigil."},{"key":"B31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s13691-022-00592-5","article-title":"Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report","volume":"12","author":"Kaitsumaru","year":"2023","journal-title":"Int. Canc. Conf. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/03009742.2020.1732462","article-title":"Olaparib-related seronegative inflammatory arthritis: f\u0131rst report in the literature","volume":"50","author":"Kobak","year":"2021","journal-title":"Scand. J. Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s13256-022-03666-3","article-title":"Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report","volume":"16","author":"Kobayashi","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3969\/j.issn.1674-0904.2026.01.011","article-title":"Niraparib maintenance therapy-induced dysgeusia following surgery for ovarian clear cell carcinoma: a case report(in Chinese)","volume":"39","author":"Lei","year":"2026","journal-title":"J. Cancer. Control. Treat."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1542646","DOI":"10.3389\/fonc.2025.1542646","article-title":"Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review","volume":"15","author":"Li","year":"2025","journal-title":"Front. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1080\/00498254.2020.1737759","article-title":"Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor","volume":"50","author":"Liao","year":"2020","journal-title":"Xenobiotica"},{"key":"B38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3969\/j.issn.1674-0904.2024.03.011","article-title":"A case of acquired amegakaryocytic thrombocytopenic purpura caused by niraparib(in Chinese)","volume":"37","author":"Ling","year":"2024","journal-title":"J. Cancer Control Treat."},{"key":"B39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/IMCRJ.S491062","article-title":"Stem cell transplantation for ovarian cancer patient with associated myelodysplasia after maintenance therapy with olaparib: a case report","volume":"18","author":"Linn","year":"2025","journal-title":"Int. Med. Case Rep. J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"815265","DOI":"10.3389\/fonc.2022.815265","article-title":"Comparative efficacy and safety of poly (ADP-Ribose) polymerase inhibitors in patients with ovarian cancer: a systematic review and network meta-analysis","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","article-title":"Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database","volume":"162","author":"Ma","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/PL00000234","article-title":"Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase","volume":"50","author":"Mabley","year":"2001","journal-title":"Inflamm. Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1684\/ejd.2022.4343","article-title":"Olaparib-induced cutaneous vasculitis in a patient with recurrent ovarian cancer","volume":"32","author":"Maiko","year":"2022","journal-title":"Eur. J. Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/ph16091261","article-title":"Niraparib and advanced ovarian cancer: a beacon in the Non-BRCA mutated setting","volume":"16","author":"Maiorano","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1038\/s41598-022-07319-9","article-title":"Evaluation of phototoxicity induced by the anticancer drug rucaparib","volume":"12","author":"Mateos-Pujante","year":"2022","journal-title":"Sci. Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/00498254.2016.1241449","article-title":"In vitro assessment of the roles of drug transporters in the disposition and drug\u2013drug interaction potential of olaparib","volume":"47","author":"McCormick","year":"2017","journal-title":"Xenobiotica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.36401\/JIPO-20-33","article-title":"First-line PARP inhibitors\u2014emerging side effects require caution: a case of PARPi-Induced pneumonitis","volume":"4","author":"McLaren","year":"2021","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/BF01534394","article-title":"Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase","volume":"19","author":"Miesel","year":"1995","journal-title":"Inflammation"},{"key":"B52","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"Mirza","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.4049\/jimmunol.177.9.6489","article-title":"Poly(ADP-ribose) Polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5","volume":"177","author":"Mustapha","year":"2006","journal-title":"J. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14740338.2024.2376690","article-title":"PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database","volume":"23","author":"Ren","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40262-019-00754-4","article-title":"Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment","volume":"58","author":"Rolfo","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","article-title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study","volume":"170","author":"Roubaud","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e97299","DOI":"10.7759\/cureus.97299","article-title":"Immune-mediated thrombocytopenia induced by niraparib: a clinically relevant case","volume":"17","author":"Roxo","year":"2025","journal-title":"Cureus"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e44864","DOI":"10.7759\/cureus.44864","article-title":"Development of erythema nodosum after olaparib treatment in a patient with recurrent breast cancer and BRCA2 mutation: a case report","volume":"15","author":"Saito","year":"2023","journal-title":"Cureus"},{"key":"B63","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000530981","article-title":"Olaparib-induced purpuric drug eruption in a patient with castration-resistant prostate cancer","volume":"16","author":"Sekine","year":"2023","journal-title":"Case Rep. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JOP.18.00705","article-title":"Olaparib-induced severe folate deficiency in a patient with advanced ovarian cancer","volume":"15","author":"Shammo","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"B66","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/jjco\/hyad171","article-title":"Interstitial lung disease caused by niraparib in ovarian cancer patient: a case report and literature review","volume":"54","author":"Shono","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3969\/j.issn.2096-3327.2024.03.009","article-title":"Clinical pharmacist participated in the treatment practice of a prostate cancer patient with olaparib induced interstitial pneumonia accompanied by fever (in Chinese)","volume":"21","author":"Si","year":"2024","journal-title":"China Ration. Drug Use"},{"key":"B68","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-3083.2005.01570.x","article-title":"Immunology of cutaneous vasculitis associated with both etanercept and infliximab","volume":"61","author":"Srivastava","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.clindermatol.2025.09.021","article-title":"Lymphocytic and granulomatous cutaneous small-vessel vasculitis after polyadenosine diphosphate\u2013ribose polymerase inhibitor therapy","volume":"43","author":"Stephan","year":"2025","journal-title":"Clin. Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3760\/cma.j.cn114015-20230727-00559","article-title":"Olaparib-induced eosinophilic pneumonia(in Chinese)","volume":"26","author":"Sun","year":"2024","journal-title":"Adverse Drug React. J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/hep.30119","article-title":"A case of immune\u2010mediated liver injury induced by olaparib","volume":"68","author":"Tufoni","year":"2018","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"103984","DOI":"10.1016\/j.esmoop.2024.103984","article-title":"Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights","volume":"9","author":"Tuninetti","year":"2024","journal-title":"ESMO Open"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.3390\/ijms22084203","article-title":"Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13223-025-00959-2","article-title":"Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) caused by niraparib: a novel antineoplastic agent","volume":"21","author":"V\u00e1zquez-Barrera","year":"2025","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.11669\/cpj.2021.20.007","article-title":"Pharmaceutical care for olaparib-induced thrombocytopenia in a platinum-sensitive recurrent ovarian cancer patient","volume":"56","author":"Wang","year":"2021","journal-title":"Chin. Pharm. J."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.19803\/j.1672-8629.20230166","article-title":"Pharmaceutical monitoring of a patient with grade IV bone marrow suppression induced by olaparib(in Chinese)","volume":"20","author":"Wang","year":"2023","journal-title":"Chin. J. Pharmacovigil."},{"key":"B79","doi-asserted-by":"publisher","first-page":"853211","DOI":"10.3389\/fonc.2022.853211","article-title":"Case report: niraparib-related pulmonary embolism during the treatment of BRCA mutant advanced ovarian cancer","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"9529821","DOI":"10.1155\/2018\/9529821","article-title":"A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer","volume":"2018","author":"Wheelden","year":"2018","journal-title":"Case Rep. Oncol. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"539","DOI":"10.19460\/j.cnki.0253-3685.2022.05.028","article-title":"A case of severe thrombocytopenia induced by niraparib(in Chinese)","volume":"48","author":"Xu","year":"2022","journal-title":"Jiangsu Med. J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3760\/cma.j.cn114015-20221103-01023","article-title":"Yao HR, liu SK. Myelodysplastic syndrome associated with olaparib(in Chinese)","volume":"25","author":"Yao","year":"2023","journal-title":"Adverse Drug React. J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3760\/cma.j.cn114015-20220215-00124","article-title":"Olaparib induced immune thrombocytopenia(in Chinese)","volume":"24","author":"Yuan","year":"2022","journal-title":"Adverse Drug React. J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/10781552231197808","article-title":"Niraparib-induced pure red cell aplasia","volume":"30","author":"Y\u00fccel","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2021.02.013","article-title":"Cigarette smoke-inactivated SIRT1 promotes autophagy-dependent senescence of alveolar epithelial type 2 cells to induce pulmonary fibrosis","volume":"166","author":"Zhang","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.13748\/j.cnki.issn1007-7693.20233165","article-title":"Increase of creatine phosphokinase induced by niraparib: a case report(in Chinese)","volume":"41","author":"Zhao","year":"2024","journal-title":"Chin. J. Mod. Appl. Pharm."},{"key":"B87","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","article-title":"Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: real-World data from a multicenter Study in China","volume":"18","author":"Zhao","year":"2023","journal-title":"Targ. Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"101439","DOI":"10.1016\/j.gore.2024.101439","article-title":"Challenges in PARP inhibitor therapy: a case of Olaparib-induced liver injury and successful rechallenge with niraparib","volume":"54","author":"Zhu","year":"2024","journal-title":"Gynecol. Oncol. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1935594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:44:19Z","timestamp":1790228659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1935594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":88,"alternative-id":["10.3389\/fphar.2026.1935594"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1935594","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1935594"}}